Legal Battle Rising: Skye Bioscience Faces Class Action Lawsuit Over Securities Violations

Skye Bioscience Under Fire: Class Action Lawsuit Filed

In a significant development on December 8, 2025, Skye Bioscience, Inc. finds itself embroiled in a class action lawsuit alleging serious violations of the securities laws. The DJS Law Group, which serves as legal counsel for the plaintiffs, is calling on affected investors to come forward and explore their rights in the wake of these alarming allegations.

The lawsuit pertains to violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 as established by the U.S. Securities and Exchange Commission (SEC). This case is particularly pertinent for shareholders of Skye Bioscience who purchased shares during the specified class period from November 4, 2024, to October 3, 2025. Investors are encouraged to contact the DJS Law Group regarding potential lead plaintiff roles in the ongoing litigation.

The Crux of the Complaint

According to the filing, Skye Bioscience has allegedly issued misleading statements regarding the efficacy of its drug, nimacimab. The complaint asserts that the company misrepresented its product's effectiveness, which has led to significant financial losses for shareholders. As specified in the suit, Skye's public communications during the class period were found to be materially misleading, fostering a false sense of security among investors.

Implications for Shareholders

For individuals who held shares of Skye during the designated timeframe, there is a pressing opportunity to participate in the lawsuit. The DJS Law Group has indicated that register shareholders will be enrolled in a portfolio monitoring system that will keep them updated on the status of the case. Importantly, there is no financial obligation for investors to join the lawsuit, which aims to recover losses sustained due to the alleged misstatements.

Next Steps for Investors

Investors who believe they may have been affected by these developments are encouraged to take action promptly. As a reminder, the deadline for involvement in this class action suit is January 16, 2026. Potential plaintiffs can reach out to the DJS Law Group to discuss the specifics of their cases and evaluate their positions as possible lead plaintiffs.

Why Choose DJS Law Group?

The DJS Law Group prides itself on its commitment to enhancing investor returns through vigorous legal advocacy and balanced counsel. Specializing in securities class actions and corporate governance litigation, the firm has established a reputation for robust representation across a range of investment sectors. DJS Law Group has worked with large hedge funds and alternative asset managers, underscoring their adept handling of complex litigation claims.

This situation underscores the vital nature of compliance with securities regulations and the significance of truthful communication in maintaining investor trust. As the legal proceedings unfold, all eyes will be on Skye Bioscience and the broader implications for the biotech sector.

Stay informed about ongoing litigation and consider your potential strategies in light of this significant lawsuit. The outcome may set a precedent in shareholder rights and corporate accountability within the life sciences industry.